Skip to Content
Merck
All Photos(1)

Key Documents

SML3069

Sigma-Aldrich

NVP-2

≥98% (HPLC)

Synonym(s):

4-[[[5′-Chloro-2′-[[trans-4-[[(1R)-2-methoxy-1-methylethyl]amino]cyclohexyl]amino][2,4′-bipyridin]-6-yl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile, NVP2

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C27H37ClN6O2
CAS Number:
Molecular Weight:
513.07
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[C@H](COC)N[C@@H]1CC[C@@H](NC2=NC=C(Cl)C(C3=NC(NCC4(CCOCC4)[N+]#[C-])=CC=C3)=C2)CC1

Biochem/physiol Actions

NVP-2 is an ATP-competitive, highly potent and selective cyclin-dependent kinase CDK9 inhibitor (human Cdk9/CycT1 IC50 = 0.3 nM with 6 μM ATP; DYRK1B IC50 = 350 nM; CDK7 IC50 >10 ?M; 0-63% inhibition of 366 other kinases at 1 μM, including CDK2/3/4/5/8). NVP-2 inhibits RNA Pol II-mediated transcription by blocking Cdk9-dependent RNA Pol II CTD phosphorylation (250 nM for 1-24 hrs; MOLT4 cells), displaying higher apoptosis-inducing and antiproliferation efficacy than the CDK2/7/9 inhibitor SNS-032 (BMS-387032) in leukemia cultures (MOLT4 IC50 = 9 nM/NVP-2 vs. 173 nM/SNS-032).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Phillip Wright et al.
Archives of toxicology, 93(3), 659-671 (2019-01-09)
Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The
Yang Gao et al.
Cell chemical biology, 25(2), 135-142 (2017-12-26)
Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clinical evolution. Here, we demonstrate upregulation of multidrug
Matthias Muhar et al.
Science (New York, N.Y.), 360(6390), 800-805 (2018-04-07)
Defining direct targets of transcription factors and regulatory pathways is key to understanding their roles in physiology and disease. We combined SLAM-seq [thiol(SH)-linked alkylation for the metabolic sequencing of RNA], a method for direct quantification of newly synthesized messenger RNAs
Georg E Winter et al.
Molecular cell, 67(1), 5-18 (2017-07-05)
Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control. A small number of regulatory factors influence transcription elongation on a global scale. Prior research using small-molecule BET bromodomain inhibitors
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service